Skip to main content
main-content

01.12.2011 | Case report | Ausgabe 1/2011 Open Access

Journal of Medical Case Reports 1/2011

Transient myeloproliferative disorder in a newborn with down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: A case report

Zeitschrift:
Journal of Medical Case Reports > Ausgabe 1/2011
Autoren:
Athanasios Tragiannidis, Zoe Dorothea Pana, Theodotis Papageorgiou, Emmanuel Hatzipantelis, Maria Hatzistilianou, Fani Athanassiadou
Wichtige Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

AT made the diagnosis of hematological disease and wrote the case report. ZDP contributed to the writing and the diagnostic procedures of the case report. TP analyzed and interpreted the data from our patient regarding the hematological disease and was responsible for our patient's treatment and care. EH was responsible for our patient's treatment and follow-up. MH analyzed and interpreted the data from our patient regarding the immunophenotype of the hematological disease. FA analyzed and interpreted the data from our patient regarding hematological disease, and was responsible for our patient's treatment and care as well as for the writing and revision of the manuscript. All authors contributed equally to the final draft of the manuscript, and read and approved the final manuscript.

Abstract

Introduction

Transient myeloproliferative disorder is a hematologic abnormality characterized by an uncontrolled proliferation of myeloblasts in peripheral blood and bone marrow that primarily affects newborns and babies with Down syndrome. Tumor lysis syndrome is rarely associated with transient myeloproliferative disorder.

Case presentation

Transient myeloproliferative disorder was diagnosed in a seven-day-old baby girl with Down syndrome, who was referred to our department due to hyperleukocytosis. Our patient developed tumor lysis syndrome, successfully treated with rasburicase, as a complication of transient myeloproliferative disorder resulting from rapid degradation of myeloid blasts after initiation of effective chemotherapy.

Conclusions

Tumor lysis syndrome is rarely reported as a complication of transient myeloproliferative disorder. To the best of our knowledge, this is the first case of a newborn with Down syndrome and transient myeloproliferative disorder treated with rasburicase for developing tumor lysis syndrome.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2011

Journal of Medical Case Reports 1/2011 Zur Ausgabe